Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Invictus MD Strategies Corp (IVITF)

Invictus MD Strategies Corp (IVITF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0780 +15.38%
on 11/19/19
0.1306 -31.09%
on 11/11/19
-0.0284 (-23.99%)
since 10/21/19
3-Month
0.0780 +15.38%
on 11/19/19
0.2760 -67.39%
on 08/23/19
-0.1650 (-64.71%)
since 08/21/19
52-Week
0.0780 +15.38%
on 11/19/19
1.0400 -91.35%
on 11/23/18
-0.9400 (-91.26%)
since 11/21/18

Most Recent Stories

More News
INVICTUS PROVIDES UPDATE ON ACREAGE PHARMS LTD. AND AB LABORATORIES INC.

INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX: IVITF; FRA: 8IS2) Marc Ripa, Interim Chief Executive Officer and Chief Operating Officer of Invictus, is pleased to report...

IVITF : 0.0900 (-9.09%)
INVICTUS AND AUTHENTIC BRANDS GROUP MUTUALLY AGREE TO TERMINATE LICENSE AGREEMENT

Vancouver, B.C., October 23, 2019 - INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX: IVITF; FRA: 8IS2) The Company and ABG-HMX, LLC ("ABG") have mutually agreed to an early...

IVITF : 0.0900 (-9.09%)
Cannabis Stocks Are "No Place to Put Your Money" Reviewers Warn

USA News Group - While it may appear very enticing to jump in on the legalization of cannabis by investing in the sector, leading reviewers are coming out strong against putting your money in pot stocks....

IVITF : 0.0900 (-9.09%)
GENE.VN : 0.115 (-11.54%)
CXXI.CN : 0.710 (-6.58%)
CXXIF : 0.5200 (-9.08%)
BE.CN : 0.030 (unch)
BLEVF : 0.0250 (+20.77%)
ICNB : 0.6499 (+8.32%)
INVICTUS CLOSES SALE OF FUTURE HARVEST DEVELOPMENT LTD.

Vancouver, BC, October 17, 2019 - INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX: IVITF; FRA: 8IS2) the Company is pleased to announce the completion, effective October 16,...

IVITF : 0.0900 (-9.09%)
INVICTUS ANNOUNCES APPOINTMENT OF INTERIM CEO AND ALTERNATE DIRECTOR

Vancouver, BC, October 8, 2019 - INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX: IVITF; FRA: 8IS2) announces that, due to health complications, Trevor Dixon, President, CEO...

IVITF : 0.0900 (-9.09%)
INVICTUS CLOSES SALE OF 0989561 BC LTD. DBA CANANDIA BIOCEUTICALS

IVITF : 0.0900 (-9.09%)
INVICTUS ENTERS INTO AGREEMENT TO SELL FUTURE HARVEST DEVELOPMENT LTD.

Vancouver, BC, September 20, 2019 - INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX: IVITF; FRA: 8IS1) announces that, the Company has agreed to sell the 82.5% issued and...

IVITF : 0.0900 (-9.09%)
INVICTUS ANNOUNCES AB LABORATORIES INC. RECEIVES AMENDED LICENSE

Vancouver, BC, September 11, 2019 - INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX: IVITF; FRA: 8IS2) is pleased to announce that AB Laboratories Inc. ("AB Labs") a company...

IVITF : 0.0900 (-9.09%)
INVICTUS SELLS 0989561 BC LTD. DBA CANANDIA BIOCEUTICALS TO REDUCE OPERATIONAL COSTS AND STREAMLINE ITS OPERATIONS

EQNX::TICKER_START (TSX-V:GENE),(Other OTC:IVITF),(Boerse Frankfurt - Freiverkehr:8IS2), EQNX::TICKER_END

IVITF : 0.0900 (-9.09%)
GENE.VN : 0.115 (-11.54%)
ACREAGE PHARMS LTD. SIGNS NON-BINDING TERM SHEET FOR UP TO $6 MILLION FINANCING FROM TRICHOME FINANCIAL

EQNX::TICKER_START (TSX-V:GENE),(Other OTC:IVITF),(Boerse Frankfurt - Freiverkehr:8IS2), EQNX::TICKER_END

IVITF : 0.0900 (-9.09%)
GENE.VN : 0.115 (-11.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

The current trending strength of the market is Strong.

Long term indicators fully support a continuation of the trend.

See More Share

Trade IVITF with:

Key Turning Points

2nd Resistance Point 0.1073
1st Resistance Point 0.0987
Last Price 0.0900
1st Support Level 0.0857
2nd Support Level 0.0813

See More

52-Week High 1.0400
Fibonacci 61.8% 0.6725
Fibonacci 50% 0.5590
Fibonacci 38.2% 0.4455
Last Price 0.0900
52-Week Low 0.0780

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar